DOCSLIB.ORG

The CQUIN Learning Network 2018 Annual Meeting Summary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The CQUIN Learning Network 2018 Annual Meeting Summary The CQUIN Learning Network 2018 Annual Meeting Summary February 13-15 Maputo, Mozambique HIV LEARNING NETWORK The CQUIN Project for Differentiated Service Delivery Table of Contents Executive Summary ............................................................................................... 1 Introduction ............................................................................................................ 4 Opening Reception ................................................................................................ 6 Wafaa El-Sadr ................................................................................................................................................. 6 Miriam Rabkin ................................................................................................................................................ 6 Solange Baptiste .............................................................................................................................................. 8 Peter Ehrenkranz............................................................................................................................................ 8 Rosa Marlene Manjate Cuco ......................................................................................................................... 9 Coverage – Taking DSD to Scale ........................................................................... 6 Setting the Scene........................................................................................................................................... 11 Mapping DSD Scale-Up .............................................................................................................................. 13 Taking DSD for Stable Patients to Scale .................................................................................................. 14 Optimizing Treatment at Scale ................................................................................................................... 16 Quality – Ensuring Effective, Patient-Centered Services ................................... 17 Beyond “Stable” Patients (Part 1) .............................................................................................................. 17 Beyond “Stable” Patients (Part 2) .............................................................................................................. 18 DSD Scale-Up: Successes, Challenges, and Key Questions .................................................................. 19 Parellel Breakout Sessions ........................................................................................................................... 20 Impact – Assessing DSD Outcomes .................................................................... 24 Measuring Impact – Monitoring, Evaluation & Research ..................................................................... 24 M&E of DSD ............................................................................................................................................... 25 Parellel Breakout Sessions ........................................................................................................................... 26 Country Breakout Sessions ......................................................................................................................... 29 Closing Remarks .................................................................................................. 33 Agenda .................................................................................................................. 35 Participants ........................................................................................................... 39 Full Transcripts .................................................................................................... 71 Country Posters .................................................................................................... 82 CQUIN is made possible with funding from the Bill & Melinda Gates Foundation. The findings and conclusions contained within this report are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. Executive Summary Background In March 2017, ICAP at Columbia University launched the HIV Coverage, Quality, and Impact Network (CQUIN), with support from the Bill & Melinda Gates Foundation. In its first year, the CQUIN learning network expanded from six to ten countries, and now includes Cote d’Ivoire, Ethiopia, Kenya, Malawi, Mozambique, South Africa, Swaziland, Uganda, Zambia, and Zimbabwe. CQUIN has fostered ongoing knowledge exchange on the implementation and scale-up of differentiated service delivery (DSD) for HIV; hosted workshops, seminars, webinars, and journal clubs; and has supported south-to-south exchange visits, technical assistance, and catalytic research projects. The network launched three virtual communities of practice focusing on M&E of differentiated services, DSD for patients at high risk for HIV disease progression, and DSD for adolescents. CQUIN also introduced the CQUIN DSD dashboard, a self-assessment tool that helps ministries of health describe the stage of DSD scale-up in their countries. The CQUIN annual meeting allowed countries to review global DSD best practices, assess their progress, exchange tools and resources, and identify their priorities for 2018. It also allowed ICAP, as the convening organization, to receive feedback from network members and advisory group members on the network’s performance and priorities for year two. Meeting Dates and Objectives The Ministry of Health of Mozambique hosted the annual meeting in Maputo, from February 12 to 15, 2018. The objectives were to: Review progress towards DSD scale-up amongst network countries Facilitate exchange of knowledge, resources, and strategies for taking DSD models (DSDM) to national scale Share research findings, best practices, and innovations in DSDM for diverse patient groups Review initial experiences and outputs of the CQUIN communities of practice Identify common gaps, challenges, and opportunities for future joint-learning, co-creation of tools and resources, and future south-to-south exchange visits Meeting Participants Representatives from Ethiopia, Kenya, Malawi, Mozambique, South Africa, Swaziland, Uganda, Zambia, and Zimbabwe attended the meeting. Cote d’Ivoire had joined the network only weeks before the meeting, and was therefore unable to attend. Country teams included representatives from ministries of health, civil society, academic institutions, and PEPFAR implementing partners. Representatives from the Bill and Melinda Gates Foundation, the U.S. Centers for Disease Prevention and Control (CDC), the World Health Organization (WHO), the United Nations Children’s Fund (UNICEF), the Joint United Nations Programme on HIV and AIDS (UNAIDS), the Global Fund (GF), the Elizabeth Glazer Pediatric AIDS Foundation (EGPAF), Médecins Sans Frontières (MSF), the International AIDS Society (IAS), the International Treatment Preparedness Coalition (ITPC), and the Global Forum on MSM and HIV (MSMGF), also attended. 1 Key Issues Presented/Discussed Dr. Wafaa El-Sadr, ICAP Global Director, set the stage for the three-day meeting. She highlighted the remarkable global scale-up of HIV treatment, especially in Sub-Saharan Africa, noting that coverage and health systems gaps remain. While scaling up DSD is not a panacea, it is one important strategy to achieve HIV epidemic control and a priority for many ministries of health. Dr. Nathan Ford, Scientific Officer, Department of HIV/AIDS & Global Hepatitis, reviewed data on national policies in the AFRO region, which demonstrate increasing national support for DSD. Many countries have policy guidelines supportive of reducing the frequency of clinic visits and medication pickups; support for community-based treatment services is more variable. CQUIN dashboard data presented by the network countries validated these findings, showing impressive progress towards a foundation for DSD scale-up, with expanding availability of supportive policies, guidelines, job aids, and training materials. This positions countries for a broad geographic scale-up of DSDM in the coming years. Dr. Miriam Rabkin, CQUIN Principal Investigator, and Dr. Peter Preko, CQUIN Project Director, highlighted key network activities and the year’s achievements. Three previous CQUIN workshops generated 24 action plans across nine countries. Of 132 action items, two-thirds are completed or are ongoing. Examples of south-to-south visits from Mozambique to Swaziland and Malawi, and from Swaziland to Malawi, demonstrated how exchange of best practices between the countries are informing guideline changes and adoption of new models. Ms. Solange Baptiste, ITPC Executive Director, presented community perspectives on DSD and stressed the need for more community engagement and education. Citing data from a rapid assessment with healthcare workers and people living with HIV (PLHIV) on their readiness for DSD, she noted that the majority of community members surveyed did not fully understand what DSD is. The Annual Meeting included 14 sessions: six panel discussions, moderated sessions, plenary presentations, and parallel breakout sessions. There were also daily poster sessions displaying progress made by each of the network countries towards DSD scale-up, as well as posters from implementing partners. One highlight of the meeting was a vibrant
Load more

Recommended publications
  • Page 1 2 0 0 7 a N N U a L R E P O R T
    2007 ANNUAL REPORT IN SEARCH OF LASTING SOLUTIONS TO HIV/AIDS THE FOUNDATION FOR AIDS RESEARCH amfAR, THE FOUNDatION F O R A ID S R E S E ar C H , I S DEDICatED TO ENDING THE GLOBAL AIDS EPIDEMIC T H R O U G H I N N O V at I V E RESEARCH. Cover photos (from top): TREAT Asia Community Programs Manager Jennifer I-Ching Ho holds an HIV-positive child (photo: Karl Grobl); Dr. Nolwenn Jouvenet, Aaron Diamond AIDS Research Center (photo: Dr. Rowena Johnston); Shan Grant, Miguel Rivera, and Robert Green (photo: Winnie McCroy). FROM THE CHAIRMAN 02 A Global Force Against a Global Epidemic FROM THE CHIEF EXECUTIVE OFFICER 03 Good Research Drives Good Policy PEOPLE LIVING WITH HIV/AIDS 04 MAJOR ACCOMPLISHMENTS 06 RESEARCH 08 GLOBAL INITIATIVES 15 PUBLIC POLICY 22 EDUCATION AND INFORMATION 26 GIVING 30 Individual Giving Institutional Giving In-Kind Contributions Planned Giving Volunteer Support Workplace Giving FINANCIAL SUMMARY 44 From the Treasurer and the Chair of the Finance and Budget Committee Statement of Activities and Changes in Net Assets Statement of Financial Position LEADERSHIP AND ADVISORY COMMITTEES 46 ACKNOWLEDGMENTS FROM THE CHAIRMAN A Global FORCE AGAINST A Global EPIDEMIC Of the 33 million people living with HIV/AIDS, more than 90 percent are in the develop- ing world. For most of its 23 years at the leading edge of the fight against AIDS, amfAR has brought AIDS research, prevention, and education to countries hard hit by the epidemic. A global health threat demands nothing less than a global response.
    [Show full text]
  • Amfar the Foundation for AIDS Research Annual Report 2010 Making AIDS History Contents
    amfAR The Foundation for AIDS Research Annual Report 2010 Making AIDS History Contents From the Chairman and the CEO 03 amfAR in 2010: Selected Accomplishments 04 Grants, Fellowships, and Awards 06 Research Grants TREAT Asia Awards MSM Initiative Awards Public Policy Awards Message from the Treasurer and the Chair of the Finance and Budget Committee 14 Financial Highlights 15 Leadership and Advisory Committees 18 Board of Trustees Scientific Advisory Committee Program Advisory Council Management Group 2 From the Chairman and the CEO As we commemorate amfAR’s 25 years in the vanguard of the global response to HIV/AIDS, we find ourselves energized by a surge of momentum and vibrancy in the field of AIDS research. We sometimes struggle to explain the nature of this sea change that has made us more optimistic than ever before about our chances of finding a cure. Here’s one way to think about it. For many years, AIDS research focused almost exclusively on trying to define the enemy—mapping out the way in which HIV invaded the human body and set about destroying the immune system. It was a little like shining a flashlight in the dark. What you’re able to see appears with great clarity. The trouble is, you’re never really sure how vast the darkness is. The research progress we’ve made in the last few years has effectively switched on the lights. Now, at last, we can see where we’re going and chart a path forward. In fact, several potential pathways are now laid out before us.
    [Show full text]
  • Annual Report 2016 Amfar,The Foundation for AIDS Research Contents
    Annual Report 2016 amfAR,The Foundation for AIDS Research Contents amfAR in 2016 01 Grants, Fellowships, and Awards 07 Research Grants, Fellowships, and Awards TREAT Asia Grants and Awards GMT Initiative Awards Public Policy Awards Financial Highlights 13 Leadership and Advisory Committees 15 Board of Trustees Scientific Advisory Committee Program Advisory Council Management Group amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research. amfAR in 2016 amfAR CEO Kevin Robert Frost flanked by Dr. Paul Volberding, director of the amfAR Institute for HIV Cure Research (left), and amfAR Chairman Kenneth Cole Research u ARCHE, the amfAR Research Consortium on HIV Eradication, Countdown to a Cure for AIDS was launched in 2010. It supports collaborative teams of scientists in the U.S. and around the world working on a range of In 2015, amfAR announced a $100 million investment strategy to HIV cure strategies. support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by 2020. The strategy u The Opportunity Fund is a funding mechanism that enables represents an unprecedented expansion of amfAR’s grant making amfAR to respond quickly to emerging and unforeseen research and is designed to provide support to any scientist or team of opportunities. investigators for any research idea with the potential to advance the search for a cure, at any stage of its development. Innovation Grants In just the first 24 months of the initiative, amfAR has supported 139 principal investigators and key personnel in 16 U.S.
    [Show full text]
  • Innovations May 2018
    INNOVATIONS MAY 2018 The Passing of a Pioneer Remembering Dr. Mathilde Krim Also Inside: A Trove of Data on the Opioid Epidemic Bioengineering Projects Advance Why Has Asia Fallen Behind on HIV/AIDS? amfAR, The Foundation for AIDS Research amfar.org COVER STORY 10 -11 MAY 2018 Dr. Mathilde Krim, AIDS Research The biannual newsletter of amfAR, Pioneer and Human Rights Leader, 1926−2018 The Foundation for AIDS Research amfAR’s Founding Chairman, who died peacefully at 120 Wall Street, 13th Floor her home on Long Island on January 15, was New York, NY 10005-3908 “one of the real heroes in this long struggle.” T: (212) 806-1600 F: (212) 806-1601 1100 Vermont Ave. NW Suite 600 POLICY Washington, DC 20005 T: (202) 331-8600 F: (202) 331-8606 4 Huge Gaps in Access to Opioid Addiction Treatment 5 Assessing the Impact of Medicaid Expansion on the TREAT Asia Opioid Epidemic Exchange Tower 388 Sukhumvit Road 6 amfAR Lends Data Expertise to PEPFAR Planning Process Suite 2104 Klongtoey, Bangkok 10110 Thailand T: (+66) 2 663-7561 RESEARCH F: (+66) 2 663-7562 www.amfar.org 7 amfAR Renews Investment in Bioengineering Approaches to Curing HIV Innovations Staff: 8 Researchers Report Progress at Cure Summit Andrew McInnes, Editor Megan Trusdell, Senior Staff Writer 9 Can “the Berlin Patient’s” Cure Be Replicated? Claudia Kaplan, Senior Staff Writer 12 New Findings Point to Power of Antibodies Raoul Norman-Tenazas, Creative Director 12 amfAR Awards Give Boost to Promising Young Yolande Hunter-Johnson, HIV/AIDS Researchers Creative Coordinator GLOBAL 13 Study Affirms Preventive Effect of HIV Treatment 13 amfAR’s Dr.
    [Show full text]
  • TAG Update 2006
    TREATMENTACTIONGROUP FALL 2006 UPDATE Dear friends of TAG– TBR&DREPORT PARIS I am very proud to send you this fall 2006 edition of TAG Update. As you can see, this has been an exciting and TB R&D Investments: A Critical Review, by Cindra Feuer, edited by productive year for the Treatment Action Group. This issue Javid Syed and Mark Harrington, was released at the 37th Union contains brief summaries of some of this year’s highlights, World Conference on Lung Health in Paris on November 3, 2006. including the release of TAG’s What’s in the Pipeline? report at The groundbreaking report established that the top 40 funders of TB the XVI International AIDS Conference in Toronto and TAG’s TB research and development (R&D) spent only $400 million on TB R&D R&D Investments: A Critical Review at the World Conference on in 2005—just 4% of what is spent on AIDS research, and far from Lung Health in Paris. There is also news about TAG’s role in what the Stop TB Partnership has estimated is needed. TAG combating the outbreak of extensively drug resistant (XDR) TB in South Africa, about Hepatitis C Coinfection Project Director presented its report at the conference and called for a five-fold Tracy Swan’s role in speeding up HCV drug development for increase in TB R&D to develop new diagnostics, drugs, and HCV/HIV coinfected persons, notes on Mark Harrington’s vaccines. The report is available from the TAG office or online at meeting with Bill and Melinda Gates at the Toronto AIDS www.treatmentactiongroup.org/tbhiv/tbrandd.pdf.
    [Show full text]
  • Cure Research Advancing on Multiple Fronts Dame Elizabeth
    SpRInG 2011 INNThe newsletter of amfAR,OV The FoundationAT for AIDS ResearchIONS Dame Elizabeth Taylor, 1932 –2011 Founding International Chairman, amfAR Dame Elizabeth Taylor was one of the most inspirational fi gures in the fi ght against HIV/AIDS. In the early years of the epidemic, she brought AIDS out of the shadows and used her celebrity to shame and cajole politicians into action. An ardent and forceful advocate, Dame Elizabeth testifi ed before Congress on the need for substantial investments in AIDS treatment, care, and research, and she raised millions for amfAR through her participation in benefi t events in the U.S. and abroad. Unfortunately, ill health prevented Dame Elizabeth from attending the amfAR New York Gala in February, when she was honored in absentia with amfAR’s Award of Courage. In his tribute remarks, Sir Elton John said, “Elizabeth Taylor was a force of nature. She compelled people to listen, made them respond, urged them to act. Elizabeth Taylor has inspired every one of us and many millions of others around the world. She has shown us the meaning of courage and moral responsibility. She’ll forever be our guiding star.” n (For more on Elizabeth Taylor’s extraordinary contributions to the fi ght against HIV/AIDS, see insert.) Cure Research Advancing on Multiple Fronts Photo: Monash University Scientifi c interest in the search for a cure for December 2010 publication in the journal HIV/AIDS has been building over the past Blood of a peer-reviewed paper on the “Berlin few years, a groundswell that is generating patient”—the HIV-positive man whose cure a critical mass of activity among researchers via a stem-cell transplant inspired new hope and scientifi c organizations, including amfAR.
    [Show full text]
  • Abbey, Cherie D., Ed. Biography Today: Scientists
    DOCUMENT RESUME ED 423 192 SO 028 991 AUTHOR Harris, Laurie Lanzen, Ed.; Abbey, Cherie D., Ed. TITLE Biography Today: Scientists & Inventors Series. Profiles of People of Interest to Young Readers. Vol. 1, 1996. ISBN ISBN-0-7808-0068-2 PUB DATE 1996-00-00 NOTE 192p. AVAILABLE FROM Omnigraphics, Inc., 2500 Penobscot Building, Detroit, MI 48226. PUB TYPE Books (010) EDRS PRICE MF01/PC08 Plus Postage. DESCRIPTORS Biographies; *Childrens Literature; *Current Events; Elementary Secondary Education; *Inventions; Popular Culture; Profiles; Recreational Reading; Reference Materials; *Role Models; *Scientists; Student Interests; Supplementary Reading Materials ABSTRACT This issue of "Biography Today" looks at scientists and inventors and is created to appeal to young readers in a format they can and enjoy and easily understand. Each entry provides at least one picture of the individual profiled, and bold-faced rubrics lead the reader to information on birth, youth, early memories, education, first jobs, marriage and family, career highlights, memorable experiences, hobbies, and honors and awards. Entries also provide information on further reading for readers. Obituary entries are included to provide a perspective on an individual's entire career. Each issue concludes with a name index, a general index, a birthplace index, and a birthday index. The scientists and inventors highlighted are John Bardeen (obituary), Sylvia Earle, Dian Fossey (obituary), Jane Goodall, Bernadine Healy, Jack Horner, Mathilde Krim, Edwin Land (obituary), Louis Leakey, Mary Leakey, Rita Levi-Montalcini, J. Robert Oppenheimer (obituary), Albert Sabin,(obituary), Carl Sagan, and James D. Watson. (RJC) ******************************************************************************** Reproductions supplied by EDRS are the best that can be made from the original document.
    [Show full text]
  • On Becoming a Leader.Pdf
    0465014088_fm.qxd:0738208175_fm.qxd 12/2/08 2:52 PM Page i More praise for On Becoming a Leader “Warren Bennis—master practitioner, researcher, and theoretician all in one—has managed to create a practical primer for leaders without sacrificing an iota of necessary subtlety and complexity. No topic is more important; no more able and caring person has attacked it.” —Tom Peters “The lessons here are crisp and persuasive.” —Fortune “This is Warren Bennis’s most important book.” —Peter Drucker “A joy to read...studded with gems of insight.” —Dallas Times-Herald “Bennis identifies the key ingredients of leadership success and offers a game plan for cultivating those qualities.” —Success “Clearly Bennis’s best work in a long line of impressive, significant contributions.” —Business Forum “Totally intriguing, thought-stretching insights into the clockworks of leaders. Bennis has masterfully peeled the onion to reveal the heartseed of leadership. Read it and reap.” —Harvey B. McKay “Warren Bennis gets to the heart of leadership, to the essence of integrity, authenticity, and vision that can never be pinned down to a manipulative formula. This book can help any of us select the new leaders we so urgently need.” —Betty Friedan “Warren Bennis’s insight and his gift with words make these lessons, from some of America’s most interesting leaders, compelling reading for every executive.” —Charles Handy 0465014088_fm.qxd:0738208175_fm.qxd 12/2/08 2:52 PM Page ii This page intentionally left blank 0465014088_fm.qxd:0738208175_fm.qxd 12/2/08 2:52 PM Page
    [Show full text]
  • In Memoriam Mathilde Krim
    Catalyst for good: in Memoriam Mathilde Krim The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Mayer, Kenneth H. 2018. “Catalyst for good: in Memoriam Mathilde Krim.” Journal of the International AIDS Society 21 (2): e25086. doi:10.1002/jia2.25086. http://dx.doi.org/10.1002/jia2.25086. Published Version doi:10.1002/jia2.25086 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014993 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Mayer KH Journal of the International AIDS Society 2018, 21:e25086 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25086/full | https://doi.org/10.1002/jia2.25086 EDITORIAL Catalyst for good: in Memoriam Mathilde Krim Kenneth H Mayer1,2,3 Corresponding author: Kenneth H Mayer, 1340 Boylston Street, Boston, Massachusetts 02215, USA. Tel: +1 617 927 6087. ([email protected]) Keywords: Mathilde Krim; amfAR; AIDS research; AIDS epidemic Received 2 February 2018; Accepted 5 February 2018 Copyright © 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. When the annals of the AIDS epidemic are finalized, the providing starter grants to new investigators to investigate key unique role of Dr.
    [Show full text]
  • When the Nation Learned in the Early 1980S That the Virus That Causes AIDS Had Begun Its Terrifying Attack Upon the Human Immune System, Dr
    When the nation learned in the early 1980s that the virus that causes AIDS had begun its terrifying attack upon the human immune system, Dr. Krim, a geneticist and virologist with wide experience in cancer research and a passion for causes, plunged into a fight not only against the virus but also for the civil rights of people who had it. Over the next several decades, she became America’s foremost warrior in the battle against superstitions, fears and prejudices that have stigmatized many people with AIDS, subjecting them to rejection and discrimination. There is still no cure for acquired immune deficiency syndrome, which has become pandemic, although antiretroviral medication can slow the disease and may lead to near- normal life expectancy with prompt diagnosis and treatment. In the early days of the American epidemic, AIDS killed large numbers of hemophiliacs, infected by tainted blood-clotting factors, and Haitians, because the virus had apparently reached the Americas there first. But the American public focused on two other high-risk groups, gay men and drug addicts, people long shunned by family-oriented Americans and the mostly heterosexual establishment. “They felt that this was a disease that resulted from a sleazy lifestyle, drugs or kinky sex — that certain people had learned their lesson and it served them right,” Dr. Krim told The New York Times Magazine in 1988. “That was the attitude, even on the part of respectable foundations that are supposed to be concerned about human welfare.” In his book “The Gay Metropolis: The Landmark History of Gay Life in America” (1997), Charles Kaiser wrote: “One scientist outside the government was more important than any other heterosexual in New York City in sounding the alarm about the growing crisis.
    [Show full text]
  • Annual Report 2018 Amfar, the Foundation for AIDS Research Cover Photo: a Dendritic Cell Interacting with a T Cell © Meletios Verras | Dreamstime.Com Awards Contents
    Annual Report 2018 amfAR, The Foundation for AIDS Research Cover photo: A dendritic cell interacting with a T cell © Meletios Verras | Dreamstime.com Awards Contents amfAR in 2018 01 Grants, Fellowships, and Awards 07 Research Grants, Fellowships, and Awards TREAT Asia Grants and Awards Public Policy Awards Financial Highlights 11 Leadership and Advisory Committees 13 Board of Trustees Scientific Advisory Committee Program Advisory Council Management Group Our Mission: amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research. Photo: Annie Leibovitz NONEVI Photo: Annie Leibovitz Dr. Mathilde Krim AIDS Research Pioneer and Human Rights Leader 1926−2018 amfAR’s revered Founding Chairman Mathilde Krim, Ph.D., died at her home on Long Island on January 15, 2018. She was 91. Dr. Krim was at the forefront of philanthropic and scientific responses to HIV/AIDS long before the world fully understood its catastrophic global reach. In April 1983, along with Dr. Joseph Sonnabend and a small group of associates, Dr. Krim founded the AIDS Medical Foundation (AMF), the first private organization concerned with fostering and supporting AIDS research. In 1985, AMF merged with a like-minded group based in California to form the American Foundation for AIDS Research (amfAR), which soon became the preeminent national nonprofit organization devoted to mobilizing the public’s generosity in support of trailblazing laboratory and clinical AIDS research, HIV prevention, and advocacy. “Dr. Krim had such a profound impact on the lives of so many,” said amfAR Chief Executive Officer Kevin Robert Frost. “While we all feel a penetrating sadness at the loss of someone we loved so deeply, it is important to remember how much she gave us and the millions for whom she dedicated her life.
    [Show full text]
  • Downloadable Version of the Complete Winter 2008 Issue
    Winter 08:Fall 11/28/07 4:19 PM Page 1 The Newsletter of amfAR, fThe Foundation for AIDS Research Winter 2008 Sharon Stone Named Global amfAR Appoints New Leadership Fundraising Chairman 2 Kevin Frost Named Chief Executive Officer POLICY REPORT mfAR has announced the appointment of Whither World Health? a Kevin Robert Frost as the Foundation’s new 3 chief executive officer. Frost was previously vice president for Global Initiatives at amfAR and has served as interim CEO since March 2007. TREAT ASIA UPDATE “amfAR’s 25 years of experience fighting AIDS 4 obligates us to do all we can in our efforts to end this pandemic,” Frost said upon his appointment. “And Fine-Tuning HAART for while the needs are great, amfAR is well positioned Treatment-Experienced to continue to make major contributions to HIV Pa5tients research, prevention, treatment, and advocacy in the coming years.” working together with civil society to build capacity RESEARCH Frost has worked extensively in Asia, where for scaling up treatment efforts in the region. HIV and the Brain he facilitated the development of amfAR’s TREAT Frost served as a member of the international amfAR to Be Honored Asia initiative, a network of more than 50 hospitals, advisory committee for the 2004 International AIDS With Adv6ocacy Award community clinics, NGOs, and healthcare facilities, Conference in Barcelona and was a member of the Rejuvenating the Field (continued on page 2) of AIDS Research 7 Global MSM Initiative Launched BENEFIT NEWS amfAR Program Addresses Shortage of HIV Services for Men Who Have Sex With Men 8 round the world, HIV remains a crisis among October and the Initiative’s initial round of grants A men who have sex with men (MSM), particu - is expected to be issued in January 2008, barely a Calendar larly in resource-limited settings.
    [Show full text]